Valuation: Adocia

Market Cap 81.59M 95.2M 76.33M 69.78M 132M 9.12B 133M 903M 351M 4.58B 357M 350M 15.15B P/E 2026 *
-761x
P/E 2027 * 6.03x
Enterprise Value 51.75M 60.38M 48.41M 44.26M 83.52M 5.78B 84.41M 573M 223M 2.9B 227M 222M 9.61B EV / Sales 2026 *
20.5x
EV / Sales 2027 * 3.16x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
1 week+0.58%
Current month+5.01%
1 month+11.20%
3 months-16.20%
6 months-40.46%
Current year-34.85%
1 week 4
Extreme 4
4.26
1 month 3.69
Extreme 3.694
4.28
3 years 3
Extreme 2.995
14.84
5 years 2.72
Extreme 2.725
14.84
10 years 2.72
Extreme 2.725
62.21
Manager TitleAgeSince
Chief Executive Officer 55 2023-05-10
Director of Finance/CFO - 2024-09-22
Chief Tech/Sci/R&D Officer - 2014-11-30
Director TitleAgeSince
Director/Board Member 55 2013-04-18
Chairman 80 2012-02-23
Director/Board Member 58 2013-06-17
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%+0.58%-51.63%-62.68% 95.25M
-4.31%-2.14%+65.79%+103.90% 72.12B
-4.19%+1.05%+46.47%+85.53% 65.85B
-2.72%+23.53%+7.69%-4.96% 29.28B
-1.18%-3.37%-3.37%+465.44% 27.47B
-4.71%+7.67%+47.63%+18.25% 26.7B
-1.81%+0.38%+34.14%-18.33% 20.06B
+5.36%-1.67%+270.18%+415.10% 18.22B
-2.79%+0.48%+12.09%+562.03% 16.4B
+0.55%+3.82%+43.32%+149.75% 13.4B
Average -1.78%+8.55%+47.23%+171.40% 32.17B
Weighted average by Cap. -2.79%+8.78%+53.84%+154.24%

Financials

2026 *2027 *
Net sales 2.52M 2.94M 2.36M 2.16M 4.07M 282M 4.11M 27.91M 10.85M 141M 11.05M 10.81M 468M 35.4M 41.31M 33.12M 30.28M 57.14M 3.96B 57.74M 392M 152M 1.99B 155M 152M 6.57B
Net income -4.32M -5.04M -4.04M -3.69M -6.97M -482M -7.04M -47.79M -18.58M -242M -18.91M -18.5M -801M -44.33M -51.72M -41.47M -37.91M -71.54M -4.95B -72.3M -491M -191M -2.49B -194M -190M -8.23B
Net Debt -29.84M -34.82M -27.92M -25.52M -48.17M -3.33B -48.68M -330M -128M -1.67B -131M -128M -5.54B 30.18M 35.21M 28.23M 25.81M 48.7M 3.37B 49.22M 334M 130M 1.69B 132M 129M 5.6B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
26-08-24 4.040 -2.65%
26-08-21 €4.150 +1.17%
26-08-20 €4.102 -2.66%
26-08-19 €4.214 +0.72%
26-08-18 €4.184 -0.85%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.170EUR
Average target price
9.700EUR
Spread / Average Target
+132.61%

Quarterly revenue - Rate of surprise